MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis

Inclusion Criteria: * Patients with active rheumatoid arthritis with disease duration minimum 6 months prior to screening visit * Patients who are naive to tumor necrosis factor (TNF) antagonists or any other monoclonal antibody therapies * Patients who have had an inadequate response to an adequate regimen of methotrexate Exclusion Criteria: * History of current rheumatic autoimmune disease other than RA and current inflammatory joint disease other than RA * Contraindications according to the MabThera SmPC and every serious coexisting diseases which, in the Investigator's opinion, would preclude subject participation * Positive tests for HIV, hepatitis B surface antigen (HBsAg) Anti-HBc antibody, hepatitis C antibody * Prior treatment with rituximab, other anti-CD20 mAb, anti-TNF-alpha drug or any other monoclonal antibodies * Pregnancy or lactation or women planning to get pregnant during the course of the study and/or within 12 months post last study drug infusion * Allergic reaction or intolerance to rituximab, MabionCD20 or any of their components * Severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or previous treatment of any lymphocyte-depleting therapies